



ASX Code: SIP

15 December 2014

MARKET UPDATE: SIGMA ON TRACK TO RECORD STRONG REVENUE GAINS FROM STRATEGIC INVESTMENTS

Sigma Pharmaceuticals Limited (Sigma) today confirmed it remains on track to deliver significant revenue gains in FY15/16 following a string of announcements that have positioned the business as the market leader in the wholesale pharmaceutical business in Australia.

A successful 2014 calendar year has seen Sigma announce the acquisitions of Central Healthcare Services (CHS), including the Pharmasave and Chemist King Pharmacy banners, effective from 26 May, followed by Discount Drug Store (DDS), effective 22 September. At the time of announcing DDS, Sigma guided that CHS and DDS combined would deliver over \$400m new revenue and around \$8-10 million incremental EBITDA in the first full year of operations.

Meanwhile, Sigma and Pharmacy Alliance (PA) continue to identify opportunities to drive business and member benefits from the supply and services agreement which was extended for 10-years during the year.

Mark Hooper, Sigma CEO and Managing Director commented "This year was about positioning the business for growth. With Pharmasave and Chemist King part of the Sigma group for just over 6 months, we have successfully transitioned over 90% of their wholesale business to Sigma. Meanwhile we continue to work closely with the DDS Pharmacy members, with almost 30% of wholesale business already transitioned to Sigma, and plans in place to reach 60% conversion by early next year. These will obviously have a stronger impact in 2015/16."

Sigma also confirms the 2015 full year results are scheduled to be announced on 19 March. With the business continuing to trade in line with expectations and franking credits expected to be available, Sigma will be well placed to pay a fully franked final dividend, subject to Board consideration and approval. Sigma's Annual General Meeting is scheduled for 6 May 2015.

Sue Morgan
General Counsel and Company Secretary

For further information, please contact:

Gary Woodford
Corporate Affairs Manager
Sigma Pharmaceuticals Limited
03 9215 9632
0417 399 204
gary.woodford@signet.com.au

SIGMA PHARMACEUTICALS LIMITED
ABN 15 088 417 403

PO Box 2890 (3 Myer Place) Rowville Victoria 3178 Australia
Telephone: +61 3 9215 9215 Facsimile: +61 3 9215 9799